Who are Ospemifene (Dose 1)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Toremifene; Anastrozole, Tamoxifen (open label), Low Dose Clomiphencitrat, E2Nomac, tamoxifen citrate (Tamoxifen), Metformin plus clomiphene citrate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ospemifene-dose-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Ospemifene (Dose 1) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ospemifene (Dose 1) (Ospemifene (Dose 1)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective estrogen receptor modulator (SERM). Area: Women's Health / Gynecology.

phase 3 Selective estrogen receptor modulator (SERM) Estrogen receptor (ER-α and ER-β) Women's Health / Gynecology Small molecule Live · refreshed every 30 min

Target snapshot

Ospemifene (Dose 1) (Ospemifene (Dose 1)) — Shionogi. Ospemifene is a selective estrogen receptor modulator (SERM) that acts as an estrogen agonist in vaginal tissue to treat moderate to severe dyspareunia caused by genitourinary syndrome of menopause.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ospemifene (Dose 1) TARGET	Ospemifene (Dose 1)	Shionogi	phase 3	Selective estrogen receptor modulator (SERM)	Estrogen receptor (ER-α and ER-β)
Toremifene; Anastrozole	Toremifene; Anastrozole	Peking Union Medical College Hospital	marketed	Selective estrogen receptor modulator (SERM) + aromatase inhibitor (AI)	Estrogen receptor (ER); aromatase (CYP19A1)
Tamoxifen (open label)	Tamoxifen (open label)	Oregon Health and Science University	marketed	Selective estrogen receptor modulator (SERM)	Estrogen receptor alpha (ERα)
Low Dose Clomiphencitrat	Low Dose Clomiphencitrat	University Hospital, Basel, Switzerland	marketed	Selective estrogen receptor modulator (SERM)	Estrogen receptor (ER-α and ER-β)
E2Nomac	E2Nomac	Sydney Centre for Reproductive Health Research	marketed	Selective Estrogen Receptor Modulator (SERM)	Estrogen receptor (ER-α/ER-β)
tamoxifen citrate (Tamoxifen)	tamoxifen citrate (Tamoxifen)	H. Lee Moffitt Cancer Center and Research Institute	marketed	Selective estrogen receptor modulator (SERM)	Estrogen receptor alpha (ERα)
Metformin plus clomiphene citrate	Metformin plus clomiphene citrate	University Magna Graecia	marketed	Combination therapy: biguanide + selective estrogen receptor modulator (SERM)	Insulin signaling pathway (metformin); estrogen receptor (clomiphene citrate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective estrogen receptor modulator (SERM) class)

University Hospital, Basel, Switzerland · 2 drugs in this class
AstraZeneca · 2 drugs in this class
Estetra · 1 drug in this class
Fundació Privada Eugin · 1 drug in this class
H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Oregon Health and Science University · 1 drug in this class
Samsung Medical Center · 1 drug in this class
Shandong Suncadia Medicine Co., Ltd. · 1 drug in this class
Sheba Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ospemifene (Dose 1) — Competitive Intelligence Brief. https://druglandscape.com/ci/ospemifene-dose-1. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing